Document:

<PAGE>
                                                                    EXHIBIT 10.1

                                                                  EXECUTION COPY

                                    AMENDMENT NO. 4 dated as of December 3, 2004
                           (this "Amendment"), to the Credit Agreement dated as
                           of August 1, 2001, as heretofore amended (as so
                           amended, the "Credit Agreement"), among WRIGHT
                           MEDICAL GROUP, INC., a Delaware corporation, WRIGHT
                           MEDICAL TECHNOLOGY, INC., a Delaware corporation, the
                           LENDERS from time to time party thereto, JPMORGAN
                           CHASE BANK, N.A., formerly known as The Chase
                           Manhattan Bank, as administrative agent and
                           collateral agent, and the other parties thereto.

                  A. Pursuant to the Credit Agreement, the Lenders and the
Issuing Bank have extended credit to the Borrower, and have agreed to extend
credit to the Borrower, in each case pursuant to the terms and subject to the
conditions set forth therein.

                  B. Section 6.04 of the Credit Agreement places limitations on,
among other things, the ability of the Loan Parties to make investments in, and
make or permit to exist loans or advances to, Subsidiaries that are not Loan
Parties.

                  C. Holdings and the Borrower desire to increase the ability of
Loan Parties to make investments in, and make or permit to exist loans or
advances to, Subsidiaries that are not Loan Parties. Accordingly, Holdings and
the Borrower have informed the Administrative Agent that they seek an amendment
of Section 6.04 of the Credit Agreement to increase the permitted basket for
investments by the Loan Parties in, and loans and advances by the Loan Parties
to, Subsidiaries that are not Loan Parties from 10% of the consolidated assets
of Holdings to 20% of the consolidated assets of Holdings.

                  D. Section 6.05 of the Credit Agreement places limitations on
the ability of Holdings, the Borrower and the Subsidiaries to sell, transfer,
lease or otherwise dispose of their assets.

                  E. The Borrower intends to participate in a tax-saving payment
in-lieu-of-tax program instituted by the Industrial Development Board of the
Town of Arlington, Tennessee (the "Arlington Industrial Development Board"),
pursuant to which the Borrower shall transfer title in certain of its assets to,
and thereafter lease such assets from, the Arlington Industrial Development
Board. Accordingly, Holdings and the Borrower have informed the Administrative
Agent that they seek an amendment of Section 6.05 of the Credit Agreement as set
forth herein.

                  F. The Required Lenders are willing to agree to such
amendments pursuant to the terms, subject to the conditions and to the extent
set forth herein.

                  G. Each capitalized term used and not otherwise defined herein
shall have the meaning assigned to such term in the Credit Agreement.

<PAGE>
                                                                               2

                  Accordingly, in consideration of the mutual agreements herein
contained and other good and valuable consideration, the sufficiency and receipt
of which are hereby acknowledged, the parties hereto agree as follows:

                  SECTION 1. Amendments. (a) Section 6.04 of the Credit
Agreement is hereby amended by amending and restating clauses (c) and (d)
thereof in their entirety as follows:

                  "(c) investments by (i) Holdings in the capital stock of the
         Borrower, (ii) the Borrower in the capital stock of any Subsidiary (not
         including any such Subsidiary that becomes a Subsidiary pursuant to
         such investment) and (iii) any Subsidiary in the capital stock of any
         other Subsidiary (not including any such Subsidiary that becomes a
         Subsidiary pursuant to such investment); provided that (A) any such
         shares of capital stock held by a Loan Party shall be pledged, if
         required, pursuant to the applicable Loan Document (subject to the
         limitations applicable to voting stock of a Foreign Subsidiary referred
         to in Section 5.12) and (B) the amount of investments by Loan Parties
         in Subsidiaries that are not Loan Parties, other than the sale,
         transfer or disposition of capital stock (or of substantially all the
         assets) of Wright Cremascoli Orthotechnique SA owned by the Borrower to
         Wright Medical Europe SA (directly or pursuant to an initial transfer
         to 2 Hip Holdings SAS), together with the amount of all outstanding
         loans or advances to such Subsidiaries (other than investments, loans
         or advances listed on Schedule 6.04), shall not exceed 20% of
         Consolidated Assets at the time of such investment, loan or advance and
         after giving effect thereto;

                  (d) loans or advances made by the Borrower to any Subsidiary
         and made by any Subsidiary to the Borrower or any other Subsidiary;
         provided that (i) any such loans and advances made by a Loan Party in
         respect of Indebtedness for borrowed money shall be evidenced by a
         promissory note payable upon demand and pledged in accordance with
         Section 3.02(b) of the Guarantee and Collateral Agreement and (ii) the
         outstanding amount of all such loans and advances by Loan Parties to
         Subsidiaries that are not Loan Parties, together with the amount of
         investments in such Subsidiaries (other than investments, loans or
         advances listed on Schedule 6.04), shall not exceed 20% of Consolidated
         Assets at the time of such loan or advance and after giving effect
         thereto;"

                  (b) Section 6.05 of the Credit Agreement is hereby amended by
deleting "and" after the semicolon at the end of clause (f) thereof, inserting a
new clause (g) immediately after such clause (f), redesignating the existing
clause (g) as clause (h) and amending the existing clause (g) and the final
proviso, in each case, as follows:

                  "(f) sales, transfers and dispositions of Loaner Instruments;

                  (g) transfer by the Borrower of assets, other than any real
         property, to the Industrial Development Board of the Town of Arlington,
         Tennessee, pursuant to a tax-saving payment in-lieu-of-tax program
         instituted by such Board, in an aggregate amount not to exceed
         $5,000,000; and

<PAGE>
                                                                               3

                  (h) sales, transfers and dispositions of assets not permitted
         by clauses (a) through (g) above not to exceed $7,500,000 in the
         aggregate during any fiscal year of Holdings;

         provided that all sales, transfers, leases and other dispositions
         permitted hereby (other than any transfer permitted under clause (g)
         above) shall be made for fair value and, except in the case of sales,
         transfers and other dispositions permitted under clause (b) above, for
         at least 80% cash consideration and/or pricing concessions the
         aggregate fair market value of which shall not exceed $5,000,000."

                  SECTION 2. Representations and Warranties. Each of Holdings
and the Borrower represents and warrants to each other party hereto that (a)
this Amendment has been duly executed and delivered by each of Holdings and the
Borrower and constitutes a legal, valid and binding obligation of Holdings and
the Borrower, enforceable against it in accordance with its terms, and (b) after
giving effect to this Amendment (i) the representations and warranties set forth
in Article III of the Credit Agreement are true and correct in all material
respects on and as of the date hereof, except to the extent such representations
and warranties expressly relate to an earlier date (in which case such
representations and warranties were true and correct in all material respects as
of the earlier date), and (ii) no Default or Event of Default has occurred and
is continuing.

                  SECTION 3. Effectiveness. This Amendment shall become
effective as of the date set forth above on the date on which the following
conditions are satisfied:

                  (a) the Administrative Agent (or its counsel) shall have
         received from each of Holdings, the Borrower and the Required Lenders a
         counterpart of this Amendment signed on behalf of such party; and

                  (b) the Administrative Agent shall have received all fees and
         other invoiced amounts required to be reimbursed by any Loan Party
         under the Credit Agreement.

                  SECTION 4. Effect of Amendment. Except as expressly set forth
herein, this Amendment shall not by implication or otherwise limit, impair,
constitute a waiver of, or otherwise affect, the rights and remedies of the
Lenders, the Issuing Bank, Collateral Agent or the Administrative Agent under
the Credit Agreement or any other Loan Document, and shall not alter, modify,
amend or in any way affect any of the terms, conditions, obligations, covenants
or agreements contained in the Credit Agreement or any other Loan Document, all
of which are ratified and affirmed in all respects and shall continue in full
force and effect. Nothing herein shall be deemed to entitle Holdings or the
Borrower to a consent to, or a waiver, amendment, modification or other change
of, any of the terms, conditions, obligations, covenants or agreements contained
in the Credit Agreement or any other Loan Document in similar or different
circumstances.

                  SECTION 5. Counterparts. This Amendment may be executed in
counterparts (and by different parties hereto on different counterparts), each
of which

<PAGE>
                                                                               4

shall constitute an original, but all of which when taken together shall
constitute a single contract. Delivery of an executed counterpart of a signature
page of this Amendment by telecopy shall be as effective as delivery of a
manually executed counterpart of this Amendment.

                  SECTION 6. Applicable Law. THIS AMENDMENT SHALL BE CONSTRUED
IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.

                  SECTION 7. Headings. Section headings used herein are for
convenience of reference only, are not part of this Amendment and shall not
affect the construction of, or be taken into consideration in interpreting, this
Amendment.

<PAGE>
                                                                               5

                  IN WITNESS WHEREOF, the parties hereto have caused this
Amendment to be duly executed by their respective authorized officers as of the
day and year first above written.

                                    WRIGHT MEDICAL GROUP, INC.,

                                    by      /s/ JOHN BAKEWELL
                                            ------------------------------------
                                            Name: John Bakewell
                                            Title: CFO & EVP

                                    WRIGHT MEDICAL TECHNOLOGY, INC.,

                                    by      /s/ JASON P. HOOD
                                            ------------------------------------
                                            Name: Jason P. Hood, Vice President
                                            Title: General Counsel and Secretary

                                    JPMORGAN CHASE BANK, N.A.,
                                    as a Lender and as Administrative Agent,

                                    by       /s/ STEPHANIE PARKER
                                            ------------------------------------
                                            Name: Stephanie Parker
                                            Title: Vice President

<PAGE>

                                                               SIGNATURE PAGE TO
                                                              AMENDMENT NO. 4 TO
                                             THE WRIGHT MEDICAL TECHNOLOGY, INC.
                                                    CREDIT AGREEMENT DATED AS OF
                                                                  AUGUST 1, 2001

                           Name of Lender:   Bank of America, N.A.
                                             -----------------------------------

                                    by       /s/ ELIZABETH L. KNOX
                                             -----------------------------------
                                             Name: Elizabeth L. Knox
                                             Title: SVP

<PAGE>

                                                               SIGNATURE PAGE TO
                                                              AMENDMENT NO. 4 TO
                                             THE WRIGHT MEDICAL TECHNOLOGY, INC.
                                                    CREDIT AGREEMENT DATED AS OF
                                                                  AUGUST 1, 2001

                                        CREDIT SUISSE FIRST BOSTON
                        Name of Lender: acting through its Cayman Islands Branch

                                    by  /s/ PAUL L. COLON
                                        ----------------------------------------
                                        Name:  Paul L. Colon
                                        Title: Director

                                    by  /s/ KARIM BLASETTI
                                        ----------------------------------------
                                        Name:  Karim Blasetti
                                        Title: Associate

<PAGE>

                                                               SIGNATURE PAGE TO
                                                              AMENDMENT NO. 4 TO
                                             THE WRIGHT MEDICAL TECHNOLOGY, INC.
                                                    CREDIT AGREEMENT DATED AS OF
                                                                  AUGUST 1, 2001

                           Name of Lender:   SunTrust Bank
                                             -----------------------------------

                                    by       /s/ W. BROOKS HUBBARD
                                             -----------------------------------
                                             Name:  W. Brooks Hubbard
                                             Title: Director

<PAGE>
                                                               SIGNATURE PAGE TO
                                                              AMENDMENT NO. 4 TO
                                             THE WRIGHT MEDICAL TECHNOLOGY, INC.
                                                    CREDIT AGREEMENT DATED AS OF
                                                                  AUGUST 1, 2001

                           Name of Lender: US Bank
                                           -------------------------------------

                                    by     /s/ RUSSELL ROGERS
                                           -------------------------------------
                                           Name:  Russell Rogers
                                           Title: Vice President<PAGE>

FORM OF INCENTIVE STOCK OPTION NOTICE AND AGREEMENT                 EXHIBIT 10.1

                                (BOB EVANS LOGO)

                   INCENTIVE STOCK OPTION NOTICE AND AGREEMENT

BOB EVANS FARMS, INC.       OPTIONEE:      OPTION NUMBER:

ID: 31-4421866              ADDRESS:       PLAN: FIRST AMENDED AND RESTATED 1998
                                                 STOCK OPTION AND INCENTIVE PLAN

3776 SOUTH HIGH STREET                     ID:
COLUMBUS, OH 43207

         EFFECTIVE      , YOU HAVE BEEN GRANTED AN INCENTIVE STOCK OPTION TO BUY
                 SHARES OF COMMON STOCK, PAR VALUE $0.01 PER SHARE, OF BOB EVANS
         FARMS, INC. AT AN EXERCISE PRICE OF $           FOR EACH SHARE.

         THE TOTAL EXERCISE PRICE FOR THE SHARES SUBJECT TO THIS INCENTIVE STOCK
         OPTION IS $                .

         THIS INCENTIVE STOCK OPTION WILL VEST AND BECOME EXERCISABLE OVER A
         PERIOD OF THREE YEARS ACCORDING TO THE FOLLOWING SCHEDULE:

         Vesting Date                            Number of Shares

                                       BOB EVANS FARMS, INC.

                                       BY:_______________________________
                                          STEWART K. OWENS
                                          CHAIRMAN AND CHIEF EXECUTIVE OFFICER
                                          DATE: [INSERT DATE]

<PAGE>

THIS INCENTIVE STOCK OPTION NOTICE AND AGREEMENT IS NOT A STOCK CERTIFICATE OR A
NEGOTIABLE INSTRUMENT. THE STOCK OPTION REPRESENTED BY THIS INCENTIVE STOCK
OPTION NOTICE AND AGREEMENT IS NON-TRANSFERABLE.

BY YOUR RECEIPT OF THIS INCENTIVE STOCK OPTION NOTICE AND AGREEMENT, YOU AND THE
COMPANY AGREE THAT THIS INCENTIVE STOCK OPTION IS GRANTED UNDER AND GOVERNED BY
THE TERMS AND CONDITIONS OF THE BOB EVANS FARMS, INC. FIRST AMENDED AND RESTATED
1998 STOCK OPTION AND INCENTIVE PLAN, INCLUDING THE TERMS AND CONDITIONS SET
FORTH ON THE REVERSE SIDE OF THIS INCENTIVE STOCK OPTION NOTICE AND AGREEMENT.

<PAGE>

                              BOB EVANS FARMS, INC.
                           FIRST AMENDED AND RESTATED
                      1998 STOCK OPTION AND INCENTIVE PLAN
                   INCENTIVE STOCK OPTION NOTICE AND AGREEMENT

BOB EVANS FARMS, INC. (THE "COMPANY") IS PLEASED TO INFORM YOU THAT YOU HAVE
BEEN GRANTED AN INCENTIVE STOCK OPTION ("OPTION") TO PURCHASE SHARES OF COMMON
STOCK, PAR VALUE $0.01, OF THE COMPANY ("SHARES"). YOUR OPTION HAS BEEN AWARDED
UNDER THE BOB EVANS FARMS, INC. FIRST AMENDED AND RESTATED 1998 STOCK OPTION AND
INCENTIVE PLAN (THE "PLAN"), WHICH, TOGETHER WITH THIS INCENTIVE STOCK OPTION
NOTICE AND AGREEMENT ("AGREEMENT"), SETS FORTH THE TERMS AND CONDITIONS OF THIS
OPTION AND IS INCORPORATED BY REFERENCE INTO THIS AGREEMENT. A PROSPECTUS
DESCRIBING THE PLAN IN MORE DETAIL [has been delivered to you] OR [accompanies
this Agreement]. COPIES OF THE PLAN AND THE PROSPECTUS ARE ALSO AVAILABLE AT OUR
HUMAN RESOURCES DEPARTMENT. THE PLAN AND THE PROSPECTUS CONTAIN IMPORTANT
INFORMATION AND WE URGE YOU TO REVIEW THEM CAREFULLY.

OPTION INFORMATION:

Optionee:                        [Insert Name]

Grant Date:                      [Insert grant date]

Shares Subject to the Option     [Insert Number]

Exercise Price:                  [Insert Exercise Price] per Share

Last Exercise Date:              [Insert Expiration Date]

VESTING: You may not exercise this Option until the Option has vested. The
Option will vest and become exercisable according to the following schedule with
respect to each installment of Shares:

      Vesting Date                 Number of Shares

--------------------------   -----------------------------

--------------------------   -----------------------------

--------------------------   -----------------------------

This vesting schedule may be affected if (1) you die, (2) you retire, (3) your
employment with the Company is terminated or (4) there is a change in control of
the Company, as explained later in this Agreement.

OPTION TERM: You must exercise this Option before the Last Exercise Date, or an
earlier date if you die or retire, if your employment with the Company is
terminated, or if there is a change in control of the Company (as explained
later this Agreement). After that time, this Option will become null and void.

EXERCISE: Exercising this Option means that you exchange this Option for a
number of Shares by purchasing each Share that you wish to buy at the Exercise
Price. You can only buy the number of Shares as to which the Option has vested
on the exercise date. For example, if you receive an option to buy 200 Shares
that vests in two annual installments of 100 Shares, you can buy up to 100
Shares on or after the first vesting date. You cannot buy the remaining 100
Shares until on or after the second vesting date. The number of Shares you may
purchase on any date cannot exceed the total number of as to which the Option is
vested by that date, less any Shares you previously acquired by exercising this
Option.

To exercise this Option, you must deliver to the Company (1) a written notice
that states the number of Shares you wish to buy and (2) the Purchase Price. The
Purchase Price is the Exercise Price multiplied by the number of Shares you are
buying. You may pay the Purchase Price in one of the following ways:

(1) Cash: Deliver cash, a cashier's check or a personal check to the Company in
the amount of the Purchase Price.

(2) Swap/Stock-for-Stock Exercise: Deliver to the Company Shares that you
already own which have a Fair Market Value equal to the Purchase Price. The
"Fair Market Value" of the Company's Shares, on any given date, is the last
reported sale price of the Shares on NASDAQ.

(3) Broker Assisted Exercise: Authorize a broker to sell some or all of the
Shares to be acquired through the exercise of the Option and instruct the broker
to pay the Company the portion of the sale proceeds equal to the Purchase Price
(and any tax withholding) and to pay you any sale proceeds remaining after
paying the Purchase Price and the broker's fee.

TAX WITHHOLDING: In the event that the Company determines that any federal,
state or local tax or withholding payment is required in connection with the
exercise of this Option or sale of the Shares you acquire through this Option,
the Company has the right to require these payments from you. The Company
permits you to make these payments (1) in cash (including cash resulting from a
broker assisted exercise), (2) by having the Company withhold from the Shares
you are to receive upon exercise a number of Shares having a Fair Market Value
equal to the payment due, or (3) delivering Shares to the Company that you
already own which have a Fair Market Value equal to the payment due. You must
elect one of these alternatives when you exercise this Option.

EXERCISE FOLLOWING RETIREMENT, DEATH, DISABILITY, TERMINATION OF EMPLOYMENT OR A
CHANGE IN CONTROL OF THE COMPANY:

Retirement (minimum age 55): If you retire, this Option will vest immediately
and become fully exercisable. You must exercise this Option by the Last Exercise
Date or within 90 days after retirement, whichever is earlier. After 90 days,
this Option will be converted into a non-qualified stock option and will expire
on the Last Exercise Date.

Death: If you die while employed by the Company, the unvested portion of this
Option will be cancelled. The legal representative of your estate must exercise
the vested portion of this Option by the Last Exercise Date or within one year
of the date of your death, whichever is earlier.

Disability: If your employment with the Company is terminated because you become
disabled, the unvested portion of this Option will be cancelled. You must
exercise the vested portion of this Option by the Last Exercise Date or within
one year of the date of your termination of employment, whichever is earlier.

Termination of Employment: If you voluntarily terminate your employment with the
Company, the unvested portion of this Option will be cancelled. You must
exercise the vested portion of this Option by the Last Exercise Date or within
90 days following the date you notify the Company of your intention to terminate
your employment, whichever is earlier. If your employment with the Company is
terminated by the Company for "cause" (as defined in the Plan), this Option will
be cancelled immediately (both the vested and unvested portions).

Change in Control of the Company: This Option will vest immediately and become
fully exercisable if, within 36 months after a change in control of the Company,
the Plan is terminated and not replaced simultaneously with a similar program
providing comparable benefits. A "change in control" is defined in the Plan.

<PAGE>

RESTRICTIONS ON TRANSFER OF OPTION: You may not assign, alienate, pledge, sell
or otherwise transfer this Option, and any purported transfer will be void and
unenforceable against the Company. Notwithstanding this prohibition, this Option
may be transferred by will or by the laws of descent and distribution. During
your lifetime, this Option may be exercised only by you or your guardian or
legal representative.

TAX CONSEQUENCES: This Option is intended to qualify as an "incentive stock
option" under Section 422 of the Internal Revenue Code of 1986, as amended (the
"Code"). This brief discussion of the federal tax rules that affect this Option
is provided as general information (not as personal tax advice) and is based on
the Company's understanding of federal tax laws and regulations in effect as of
the Grant Date. YOU SHOULD CONSULT WITH A TAX OR FINANCIAL ADVISER TO ENSURE YOU
FULLY UNDERSTAND THE TAX RAMIFICATIONS OF YOUR OPTION.

You will not be required to pay ordinary income taxes on the value of this
Option when it is issued, when it becomes exercisable or when you buy Shares by
exercising this Option. Also, if you comply with certain rules (discussed
below), you will not have ordinary income when you sell the

Shares you purchased through this Option. Instead, capital gains taxes will
apply, but only when you sell the Shares you bought by exercising this Option.
Also, these taxes will be applied only to the difference between the price you
paid for the Shares (i.e., the Exercise Price) and the amount you receive when
you sell the Shares. Because capital gains tax rates normally are lower than
ordinary income tax rates, this should minimize your total tax liability.
However, this favorable capital gains tax treatment is available only if you do
not sell the Shares earlier than two years after the Grant Date and one year
after you exercise this Option. You may incur a tax liability when you exercise
this Option if you pay the Purchase Price by delivering already owned shares or
using a broker assisted exercise.

If you do not comply with the rule just described, you must pay income tax, at
ordinary income tax rates, on the difference between the Exercise Price and the
fair market value of the Shares on the exercise date. Any additional gain (i.e.,
the difference between the fair market value of the Shares on the exercise date
and the amount you receive when you sell the Shares) would be taxed at capital
gains rates.

You also should know that this option is subject to an "alternative minimum
tax," which is a special tax rate imposed on tax preference items. Generally,
the alternative minimum tax structure requires that you calculate your taxes, at
a special rate, by including all items of tax preference, including the
difference between the Exercise Price and the value of the Shares you purchase
when you exercise this Option. This is done for the year in which you exercise
this Option. Then, you compare the tax calculated under the alternative minimum
tax rates with the tax you owe under the ordinary method of calculating your
taxes for that year and pay the higher of the two tax amounts. You may avoid
application of the "alternative minimum tax" by making a special election (known
as a Code Section 83(b) election) within 30 days of the Grant Date. However,
there are important tax and investment issues that you must consider before
making a Code Section 83(b) election that you should discuss with your personal
tax adviser.

PLAN CONTROLS: THE COMPANY HAS DEVELOPED THE PLAN TO ENCOURAGE YOUR CONTINUED
EFFORT AND COMMITMENT TO THE COMPANY. THE TERMS CONTAINED IN THE PLAN ARE
INCORPORATED INTO AND MADE A PART OF THIS AGREEMENT AND THIS AGREEMENT SHALL BE
GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE TERMS OF THE PLAN. IN THE EVENT
OF ANY ACTUAL OR ALLEGED CONFLICT BETWEEN THE TERMS OF THE PLAN AND TERMS OF
THIS AGREEMENT, THE TERMS OF THE PLAN SHALL BE CONTROLLING AND DETERMINATIVE.

OPTIONS AS AN INVESTMENT: DECIDING WHETHER AND WHEN TO EXERCISE THIS OPTION IS
AN IMPORTANT INVESTMENT DECISION. THE VALUE OF THIS OPTION IS THE DIFFERENCE
BETWEEN THE EXERCISE PRICE AND THE FAIR MARKET VALUE OF SHARES ON THE EXERCISE
DATE. IF THE FAIR MARKET VALUE OF THE SHARES RISES, YOU MAY REALIZE A GAIN.
HOWEVER, THERE IS NO GUARANTEE THAT THE VALUE OF THE SHARES WILL RISE. IF THE
FAIR MARKET VALUE OF THE SHARES DECLINES, YOU MAY LOSE ALL OR SOME OF YOUR
INVESTMENT.

NO RIGHTS AS A STOCKHOLDER: YOU SHALL NOT HAVE ANY RIGHTS AS A STOCKHOLDER OF
THE COMPANY WITH RESPECT TO ANY OF THE SHARES SUBJECT TO THIS OPTION UNTIL YOU
EXERCISE THE OPTION AND THE COMPANY ISSUES A CERTIFICATE TO YOU EVIDENCING SUCH
SHARES.

SECTION 16 OFFICERS AND AFFILIATES: IF YOU ARE AN EXECUTIVE OFFICER OF THE
COMPANY SUBJECT TO THE REQUIREMENTS OF SECTION 16 OF THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED, YOU ARE RESPONSIBLE FOR ENSURING THAT ALL THE REQUIREMENTS
OF SECTION 16 ARE MET, INCLUDING FILING NOTICES WITH THE SECURITIES AND EXCHANGE
COMMISSION ON FORM 4 WHEN YOU RECEIVE AND WHEN YOU EXERCISE THIS OPTION.
ADDITIONALLY, THE METHODS BY WHICH YOU MAY EXERCISE THIS OPTION MAY BE SUBJECT
TO ADDITIONAL RESTRICTIONS UNDER THE FEDERAL SECURITIES LAWS. ALSO, CERTAIN
RESTRICTIONS ARE IMPOSED BY THE FEDERAL SECURITIES LAWS ON THE RESALE OF SHARES
ACQUIRED UNDER THE PLAN BY PERSONS DEEMED TO BE "AFFILIATES" OF THE COMPANY. AN
"AFFILIATE" IS A PERSON WHO POSSESSES THE POWER (DIRECT OR INDIRECT) TO DIRECT
OR CAUSE THE DIRECTION OF THE COMPANY'S MANAGEMENT OR POLICIES.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}]]